Defining the clinical course of multiple sclerosis: 312 the 2013 revisions, Neurology, vol.83, issue.3, pp.278-286, 2014. ,
Virtual hypoxia and chronic necrosis of demyelinated axons in 314 multiple sclerosis, Lancet Neurol, vol.8, issue.3, pp.280-291, 2009. ,
Mitoxantrone in progressive multiple sclerosis: a 316 placebo-controlled, double-blind, randomised, multicentre trial, Lancet, vol.360, issue.9350, pp.317-2018, 2002. ,
Rituximab in patients with primary 319 progressive multiple sclerosis: results of a randomized double-blind placebo-controlled 320 multicenter trial, Ann Neurol, vol.66, issue.4, pp.460-471, 2009. ,
Ocrelizumab versus placebo in primary 322 progressive multiple sclerosis, N Engl J Med, vol.376, issue.3, pp.209-220, 2017. ,
Siponimod versus placebo in secondary progressive 324 multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study, Lancet, vol.325, pp.1263-1273, 2018. ,
Cerebrospinal fluid levels of biotin in 327 various neurological disorders, Acta Neurol Scand, vol.99, issue.6, pp.387-392, 1999. ,
Pharmacokinetics and 329 pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple 330 sclerosis, Expert Opin Drug Metab Toxicol, vol.12, issue.3, pp.327-344, 2016. ,
Neuroprotective potential of high-dose biotin, Hypotheses, vol.332, pp.145-149, 2017. ,
EDMUS, a European database for 342 multiple sclerosis, J Neurol Neurosurg Psychiatry, vol.55, issue.8, pp.671-676, 1992. ,
Natural, innate improvements in multiple sclerosis 344 disability, Mult Scler, vol.18, issue.10, pp.1412-1421, 2012. ,
Cladribine and progressive MS: clinical and MRI outcomes 346 of a multicenter controlled trial. Cladribine MRI Study Group, Neurology, vol.54, issue.5, pp.347-1145, 2000. ,
Multicentre, randomised, double blind, placebo 349 controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary 350 progressive multiple sclerosis, J Neurol Neurosurg Psychiatry, vol.75, issue.5, pp.706-710, 2004. ,
High dose biotin as treatment for progressive multiple sclerosis ,
, Mult Scler Relat Disord, vol.18, pp.141-143, 2017.
Effect of MD1003 (high dose pharmaceutical grade 354 biotin) on dexterity, cognitive, and quality of life measures in a cohort of patients with non, p.355 ,